Medico RemediesNSE:MEDICO -1.88%87 ROE % is 31.04% as of Mar. 2026, which is 153% above its 10-year median of 12.27. GuruFocus rates NSE:MEDICO with a GF Score™ of 87/100 and a GF Value™ of ₹75.89 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 936 Drug Manufacturers companies, Medico Remedies ranks better than 86.43% on this metric.
The historical rank and industry rank for Medico Remedies's ROE % or its related term are showing as below:
NSE:MEDICO'
s ROE % Range Over the Past 10 Years
Min: 5.61 Med: 12.27 Max: 19.21
Current: 19.21
During the past 13 years, Medico Remedies's highest ROE % was 19.21%. The lowest was 5.61%. And the median was 12.27%.
NSE:MEDICO's ROE % is ranked better than 86.43% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs NSE:MEDICO: 19.21
Medico Remedies (NSE:MEDICO) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Medico Remedies ROE % Related Terms
Medico Remedies ROE % Historical Data
* Premium members only.
The historical data trend for Medico Remedies's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medico Remedies ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's ROE % distribution charts can be found below:
* The bar in red indicates where Medico Remedies's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Medico Remedies (NSE:MEDICO) has a ROE % of 31.04% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Medico Remedies and its competitors. This is 153% above median its historical median of 12.27. Over the past decade, Medico Remedies' ROE % has ranged from 5.61 to 19.21. According to the industry distribution chart, Medico Remedies ranks #127 out of 936 companies in the Drug Manufacturers industry, placing it in the top 13.6%.
Is Medico Remedies' ROE % too high?
Medico Remedies' current ROE % of 31.04% is 153% above median its 10-year median of 12.27. Over the past 10 years, this metric has ranged from a low of 5.61 to a high of 19.21. The Drug Manufacturers industry median ROE % is 5.87. Medico Remedies' value of 31.04% is 429.2% above this industry median. Based on the distribution chart, Medico Remedies ranks #127 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medico Remedies has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medico Remedies' ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medico Remedies ranks #127 out of 936 companies for ROE %. This places Medico Remedies in the top 14% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. Medico Remedies' value of 31.04% is 429.2% above this benchmark. Historically, Medico Remedies' own ROE % has ranged from 5.61 to 19.21 over the past decade. While the company's 10-year median is 12.27 vs. the industry median of 5.87, Medico Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medico Remedies's current ROE % of 31.04% is 429.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Medico Remedies and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medico Remedies's current ROE % is 31.04%, which is 153% above median its own 10-year median of 12.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medico Remedies stock overvalued right now?
Based on GuruFocus' analysis, Medico Remedies (NSE:MEDICO) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹75.89, compared to a current price of ₹40.28 — trading 46.9% below its estimated fair value. The current ROE % is 31.04%, which is 153% above median its 10-year median of 12.27 and 429.2% above the Drug Manufacturers industry median of 5.87. Medico Remedies' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Medico Remedies (NSE:MEDICO), the current ROE % is 31.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medico Remedies (NSE:MEDICO) Overvalued in 2026?
Based on GuruFocus' analysis, Medico Remedies stock appears to be undervalued.
The current stock price of ₹40.28 is trading 46.9% below its estimated GF Value™ of ₹75.89.
GuruFocus considers Medico Remedies to be Significantly Undervalued.
Key valuation signals for NSE:MEDICO:
ROE %: 31.04% (153% above median its 10-year median of 12.27)
GF Value™: ₹75.89 vs. price of ₹40.28 (46.9% below fair value)
Industry Position: 429.2% above the Drug Manufacturers median (#127 of 936)
No single metric tells the full story. See the NSE:MEDICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It operates in single segment single segment of manufacturing medicines including Antihy pertensive Antidiabetics Antibictics Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets, so many drugs used for treatment of so many diseases for oral use as well as external preparations like creams & ointments which includes anti infectives ,antifungals ,antibiotics ,steroidal preparations etc. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.
87GF Score
Get the complete analysis for NSE:MEDICO
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDICO has been successfully added to your 
